Long-term tracking of blood and leukemia disorders

This is an observational registry — meaning researchers are not testing a new drug or treatment, but rather gathering information from patients who already have myelodysplastic syndrome or therapy-related acute myeloid leukemia. Started in 2003, the registry collects information about your health, medical history, test results, and the treatments you receive. This information helps doctors understand these blood disorders better and identify patterns that may improve care for future patients.

Myelodysplastic syndromes and therapy-related acute myeloid leukemia are rare and complex blood disorders that doctors are still learning to understand and treat. By collecting detailed information from many patients over time, researchers can identify what works best, spot new trends in the disease, and develop better treatment strategies.